Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Results
Phase 2
This trial was comparing a drug called barasertib (also known as AZD1152) with a low dose of cytosine arabinoside chemotherapy for people over 60 who had acute myeloid leukaemia (AML) and couldn’t have intensive treatment.
Recruitment start: 10 August 2009
Recruitment end: 22 July 2010
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Ghulam Mufti
AstraZeneca
Last reviewed: 12 November 2013
CRUK internal database number: 6109
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
